Perspectives on the future of postmarket vaccine safety surveillance and evaluation

References

• Ball R. Methods for ensuring vaccine safety. Expert Rev Vaccines 2002;1:161-8
   PubMedGoogle Scholar
• Ellenberg SS, Foulkes MA, Midthun KM, Goldenthal KL. Evaluating the safety of new vaccines: summary of a workshop. Am J Public Health 2005;95(5):800-7
   PubMed Web of Science ®Google Scholar
• Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006;354(1):11-22
   PubMed Web of Science ®Google Scholar
• Vesikari T, Matson DO, Dennehy P, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006;354(1):23-33
   PubMed Web of Science ®Google Scholar
• Varricchio F, Iskander J, Destefano F, et al. Understanding vaccine safety information from the vaccine adverse event reporting system (VAERS). Pediatr Infect Dis J 2004;23:287-94
   PubMed Web of Science ®Google Scholar
• Vellozzi C, Broder KR, Haber P, et al. Adverse events following influenza A (H1N1) 2009 monovalent vaccines reported to the vaccine adverse event reporting system, United States, October 1, 2009-January 31, 2010. Vaccine 2010;45:7248-55
   Google Scholar
• Woo J, Ball R, Burwen DR, Braun MM. Effects of stratification on data mining in the US vaccine adverse event reporting system (VAERS). Drug Saf 2008;31:667-74
   PubMedGoogle Scholar
• Dal Pan GJ, Lindquist M, Gelperin K. Postmarketing spontaneous pharmacovigilance reporting systems. In: Strom BL, Kimmel SE, Hennessy S, editors. Pharmacoepidemiology. 5th Edition. John Wiley and Sons, LTD; Oxford, UK: 2012. p. 137-57
   Google Scholar
• Strom BL. Basic principles of clinical epidemiology relevant to pharmacoepidemiological studies. In: Strom BL, Kimmel SE, Hennessy S, editors. Pharmacoepidemiology. 5th Edition. John Wiley and Sons, LTD; Oxford, UK: 2012. p. 38-51
   Google Scholar
• CDC. Intussusception among recipients of rotavirus vaccine – United States, 1998-1999. MMWR 1999;48:577-81
   PubMedGoogle Scholar
• Weldeselassie YG, Whitaker HJ, Farrington CP. Use of the case-series method in vaccine safety studies: review and recommendation for best practice. Epidemiol Infect 2011;139:1805-17
   PubMed Web of Science ®Google Scholar
• Black S, Eskola J, Siegrist CA, et al. Importance of background rates of disease in assessment of vaccine safety during mass immunisation with pandemic H1N1 influenza vaccines. Lancet 2009;374:2115-22
   PubMed Web of Science ®Google Scholar
• Martin D, Menschik M, Bryant-Genevier M, Ball R. Data mining for prospective early detection of safety signals in the vaccine adverse events reporting system (VAERS): A case study of febrile seizures after a 2010-2011 seasonal influenza virus vaccine. Drug Saf 2013;36:547-56
   PubMed Web of Science ®Google Scholar
• Baggs J, Gee J, Lewis E, et al. The vaccine safety datalink: a model for monitoring immunization safety. Pediatrics 2011;127(Suppl 1):S45-53
   PubMed Web of Science ®Google Scholar
• Yih WK, Kulldorff M, Fireman BH, et al. Active surveillance for adverse events: the experience of the Vaccine Safety Datalink project. Pediatrics 2011;127(Suppl 1):S54-64
   PubMedGoogle Scholar
• Burwen D, La Voie L, Braun MM, et al. Evaluating adverse events after vaccination in the Medicare population. Pharmacoepidemiol Drug Saf 2007;16:753-61
   PubMed Web of Science ®Google Scholar
• Robb MA, Racoosin JA, Sherman RE, et al. The US Food and Drug Administration's Sentinel Initiative: expanding the horizons of medical product safety. Pharmacoepidemiol Drug Saf 2012;21(Suppl 1):9-11
   PubMedGoogle Scholar
• Salmon DA, Akhtar A, Mergler MJ, et al. Immunization safety monitoring systems for the 2009 H1N1 monovalent influenza vaccination program. Pediatrics 2011;127:S78-86
   PubMedGoogle Scholar
• Burwen DR, Sandhu SK, MaCurdy T, et al. Surveillance for Guillain-Barré Syndrome after influenza vaccination among the Medicare population, 2009-2010. Am J Public Health 2012;102:1921-7
   PubMed Web of Science ®Google Scholar
• Nguyen M, Ball R, Midthun K, Lieu TA. FDA's post-licensure rapid immunization safety monitoring (PRISM) program: strengthening the federal vaccine safety enterprise. Pharmacoepidemiol Drug Saf 2012;21(S1):291-7
   PubMedGoogle Scholar
• Eurosurveillance editorial team. ECDC in collaboration with the VAESCO consortium to develop a complementary tool for vaccine safety monitoring in Europe. Euro Surveill 2009. [Epub ahead of print]
   Google Scholar
• Barker Cl, Snape MD. Pandemic influenza A H1N1 vaccines and narcolepsy: vaccine safety surveillance in action. Lancet Infect Dis 2013. [Epub ahead of print]
   PubMedGoogle Scholar
• Dodd CN, Romio SA, Black S, et al. International collaboration to assess the risk of Guillain Barré Syndrome following Influenza A (H1N1) 2009 monovalent vaccines. Vaccine 2013;31:4448-58
   PubMed Web of Science ®Google Scholar
• Salmon D, Proschan M, Forshee R, et al. A meta-analysis of the association between Guillain-Barré Syndrome and influenza A (H1N1) 2009 monovalent inactivated vaccines in the United States. Lancet 2013;381:1461-8
   PubMed Web of Science ®Google Scholar
• Braun MM. Towards better vaccine safety data and safer vaccination. Pediatrics 2008;121:625-6
   PubMedGoogle Scholar
• Poland GA, Ovsyannikova IG, Jacobson RM. Personalized vaccines: the emerging field of vaccinomics. Expert Opin Biol Ther 2008;8:1659-67
   PubMed Web of Science ®Google Scholar
• Reif DM, Motsinger-Reif AA, McKinney BA, et al. Integrated analysis of genetic and proteomic data identifies biomarkers associated with adverse events following smallpox vaccination. Genes Immun 2009;10:112-19
   PubMed Web of Science ®Google Scholar
• Ball R, Shadomy SS, Meyer A, et al. HLA-type and immune response to B. Burgdorferi outer surface protein a in people in whom arthritis developed after lyme vaccine. Arthritis Rheum 2009;60:1179-86
   PubMedGoogle Scholar
• Immunization safety review committee. immunization safety review: vaccines and autism. institute of medicine (US)). National Academies Press; Washington DC, USA: 2004
   Google Scholar
• Burwen DR, Ball R, Bryan WW, et al. Evaluation of guillain-barré syndrome among recipients of influenza vaccine in 2000 and 2001. Am J Prev Med 2010;39:296-304
   PubMedGoogle Scholar
• CDC. Withdrawal of rotavirus vaccine recommendation. MMWR 1999;48:1007
   PubMedGoogle Scholar
• Cortese MM. Summary of intussusception risk and benefits of rotavirus vaccination in the United States. Centers for Disease Control and Prevention Advisory Committee on Immunization Practices. 2013. Available from: www.cdc.gov/vaccines/acip/meetings/downloads/slides-jun-2013/06-Rotavirus-Cortese.pdf [Last accessed 26 November 2013]
   Google Scholar
• Schwartz JL. Rotavirus vaccines, intussusception, and risk-benefit assessments. JAMA Pediatr 2013;167(12):1093-4
   PubMedGoogle Scholar
• Kelly HA, Skowronski DM, DeSerres G, Effler PV. Adverse events associated with 2010 CSL and other inactivated influenza vaccines. Med J Aust 2011;195:318-20
   PubMed Web of Science ®Google Scholar
• Decade of vaccine collaboration global vaccine action plan. Vaccine 2013;31(Suppl):B5-B31
   PubMedGoogle Scholar
• Amarasinghe A, Black S, Bonhoeffer J, et al. Effective vaccine safety systems in all countries: a challenge for more equitable access to immunization. Vaccine 2013;31(Suppl 2):B108-14
   PubMedGoogle Scholar
• Elmgren L, Li X, Wilson C, et al. A global regulatory science agenda for vaccines. Vaccine 2013;31(Suppl 2):B163-75
   PubMedGoogle Scholar
• WHO. The global vaccine safety initiative. Available from: www.who.int/vaccine_safety/initiative/en/ [Last accessed 22 January 2014]
   Google Scholar
• Larson HJ, Smith DM, Paterson P, et al. Measuring vaccine confidence: analysis of data obtained by a media surveillance system used to analyse public concerns about vaccines. Lancet Infect Dis 2013;13:606-13
   PubMed Web of Science ®Google Scholar
• Bauch C, Bhattacharyya S, Ball R. Rapid emergence of free-riding behavior in new pediatric immunization programs. PLoS One 2010;5(9):e12594
   PubMedGoogle Scholar
• Shim E, Grefenstette JJ, Albert SM, et al. A game dynamic model for vaccine skeptics and vaccine believers: measles as an example. J Theor Biol 2012;295:194-203
   PubMedGoogle Scholar
• US FDA. Enhancing benefit-risk assessment in regulatory decision-making. Available from: www.fda.gov/ForIndustry/UserFees/PrescriptionDrugUserFee/ucm326192.htm [Last accessed 22 January 2014]
   Google Scholar
• IMI. Advance: accelerated development of vaccine benefit-risk collaboration in Europe. Available from: www.imi.europa.eu/content/advance [Last accessed 22 January 2014]
   Google Scholar
• Eichler HG, Oye K, Baird LG, et al. Adaptive licensing: taking the next step in the evolution of drug approval. Clin Pharmacol Ther 2012;91:426-37
   PubMed Web of Science ®Google Scholar
• Woodcock J. Evidence vs. access: can twenty-first-century drug regulation refine the tradeoffs? Clin Pharmacol Ther 2012;91:378-80
   PubMed Web of Science ®Google Scholar
• Hullermeier E. Case-based approximate reasoning. Springer: Dordrecht, The Netherlands; 2007
   Google Scholar
• Cao H, Melton GB, Markatou M, Hripcsak G. Use of abstracted patient-specific features to assist an information-theoretic measurement to assess similarity between medical cases. J Biomed Inform 2008;41:882-8
   PubMedGoogle Scholar
• CIOMS/WHO report on vaccine pharmacovigilance, council for international organizations of medical sciences (CIOMS). 2012. Available from: www.cioms.ch [Last accessed 26 November 2013]
   Google Scholar
• Botsis T, Ball R. Automating case definitions using literature-based reasoning. Appl Clin Inf 2013;4:515-27
   PubMedGoogle Scholar
• Botsis T, Nguyen MD, Woo EJ, et al. Vaccine adverse event text mining (VAETM) system for extracting features from vaccine safety reports. J Am Med Inform Assoc 2012;19:1011-18
   PubMed Web of Science ®Google Scholar
• Ball R, Botsis T. Can network analysis improve pattern recognition among adverse events following immunization reported to VAERS? Clin Pharmacol Ther 2011;90:271-8
   PubMedGoogle Scholar
• Cao H, Hripcsak G, Markatou M. A statistical methodology for analyzing co-occurrence data from a large sample. J Biomed Inform 2007;40:343-52
   PubMedGoogle Scholar
• Google Flu Trends. Available from: www.google.org/flutrends/ [Last accessed 22 January 2014]
   Google Scholar
• Ginsberg J, Mohebbi MH, Patel RS, et al. Detecting influenza epidemics using search engine query data. Nature 2009;457:1012-14
   PubMed Web of Science ®Google Scholar
• White RW, Tatonetti NP, Shah NH, et al. Web-scale pharmacovigilance: listening to signals from the crowd. J Am Med Inform Assoc 2013;20:404-8
   PubMed Web of Science ®Google Scholar
• Kass-Hout TA, Alhinnawi H. Social media in Public Health. Br Med Bull 2013;1-20
   Google Scholar
• Adedeji AA, Sanusi B, Tella A, et al. Exposure to anti-malarial drugs and monitoring of adverse drug reactions using toll free mobile phone calls in private retail sector in Sagamu, Nigeria: implications for pharmacovigilance. Malar J 2011;10:230
   PubMedGoogle Scholar
• Overhage JM, Ryan PB, Schuemie MJ, Stang PE. Desideratum for Evidence based epidemiology. Drug Saf 2013;36:S5-S14
   PubMedGoogle Scholar
• Dal Pan G. Ongoing challenges in pharmacovigilance. Drug Saf 2014;37:1-8
   PubMed Web of Science ®Google Scholar